0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 1

Integrin alpha 4 beta 1

Brief Information

Name:Integrin alpha-4/beta-1
Target Synonym:Integrin alpha4beta1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IT1-H52W1-ELISA
Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag FreeHuman ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) ELISA bioactivity

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 1-16 ng/mL (QC tested).

IT1-H82W1-ELISA
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag FreeBiotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) ELISA bioactivity

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with a linear range of 2-31 ng/mL (QC tested).

Synonym Name

Integrin alpha 4 beta 1,ITGA4&ITGB1,ITGA4&B1

Background

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Tysabri, Antegran, Antegren Japan Multiple Sclerosis Biogen Inc 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Myeloma; Stroke; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Natalizumab biosimilar (Polpharma Biologics) PB-006 Phase 3 Clinical Polpharma Biologics Multiple Sclerosis Details
LLP2A alendronate Phase 1 Clinical University Of California Osteoporosis; Bone Diseases Details
7HP-349 Phase 1 Clinical Solid tumours Details
ATL-1102 TV-1102; ATL-1102; ATL/TV-1102; ISIS-107248 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis Details
AS-101 WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101; PRX-0001/AS101 Phase 2 Clinical Biomas Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Condylomata Acuminata; Dermatitis, Atopic Details
RBx-7796 RBx-7796 Clinical Sun Pharmaceutical Industries Ltd Rhinitis, Allergic; Asthma Details

This web search service is supported by Google Inc.

totop